IPO mania fizzles in Hong Kong as mega first-day pops disappear


Last year’s largely winning investor play of piling into IPOs and exiting after they debuted is no longer a slam dunk: 31% of 13 IPOs raising more than US$100mil (RM410mil) posted losses on day one this year, almost double the 17% in 2020.

HONG KONG: The days of the massive first-day pop in Hong Kong’s initial public offering (IPO) frenzy may be nearing an end.

Even as the pandemic spread for most of 2020, the offshore Chinese city’s IPOs and new listings were in hot demand from both institutional and mom-and-pop investors.

With the bulk of new share sales posting large gains on their first-day of trading, investor euphoria was justified.

That was then. Last year’s largely winning investor play of piling into IPOs and exiting after they debuted is no longer a slam dunk: 31% of 13 IPOs raising more than US$100mil (RM410mil) posted losses on day one this year, almost double the 17% in 2020.

A median first-day move showed gains of 2.1% in 2021 from 5.7% last year, according to data compiled by Bloomberg.

Volatility sparked by the great rotation into previously unloved stocks sensitive to economic fluctuations from loftily valued tech and health-care plays is to blame, according to investors.

Others also pointed to worries about policy being tightened in China as weighing on investors’ risk appetite for new stock.

“Most IPOs performed really, really strongly last year, but I’m not expecting that kind of movement this year, ” said Joohee An, a fund manager at Mirae Asset Global Invest (HK) Ltd. Investors will be “more prudent” as market liquidity “won’t be as abundant as it used to be”, she added.

To be clear, listings by Kuaishou Technology and New Horizon Health Ltd still did unusually well in February, with shares more than doubling on the first day.

But lukewarm post-listing performances are increasing.

Chinese household insecticide company Cheerwin Group Ltd slumped as much as 20% on its first trading day last week.

Biopharmaceutical company SciClone Pharmaceuticals Holdings Ltd ended its March 3 debut flat and is now trading 8.6% below its offer price.

The secondary listing wave of US-listed Chinese companies hasn’t always had glowing debuts in Hong Kong.

Autohome Inc, a Chinese online car-sales website with its primary listing in New York, ended its Hong Kong debut last Monday with a modest 2% rise.

Not everyone is concerned, given rising concerns voiced by some that global markets were in bubble territory.

“When you have these deals that don’t do well, it actually tells you that people are still being cautious about what they’re investing in and what they’re not, which is a good sign, ” said Sumeet Singh, head of research at Aequitas Research in Singapore, who publishes on Smartkarma.

“It means the market is doing OK.”

The upcoming multi-billion dollar listings of Baidu Inc and Bilibili Inc will be closely watched to see if Hong Kong’s IPO market still has steam, given their size and high profile as tech companies.

Baidu, which priced at an almost 3% discount to its US-traded shares, will start trading tomorrow.

Investor demand for its offering was strong, with retail investors putting in orders for almost 100 times the stock made available to them, according to a source.

Bilibili, the video streaming platform that is looking to raise as much as US$3.2bil in a second listing, plans to debut on March 29.

“I am definitely not concerned, ” said Oliver Cox, a top-performing fund manager at JP Morgan Asset Management. In general, “the quality and long-term earnings growth prospects of the companies we see coming to market is still very high indeed and pricing of IPOs does not affect that” he said. — Bloomberg

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3

Hong Kong , IPO , fizzles , first day , pops disappear ,

   

Next In Business News

Malaysia Airlines, ReveMax in revenue strategy plan
Taiwan reassures on economy as stocks fall amid Covid-19 spike
Thailand 1Q slump eases, outlook cut as Covid-19 woes linger
China's industrial output growth slows in April
Maybank IB Research retains buy on BIMB
Ringgit opens easier amid ongoing Covid struggles
AmInvest Research keeps buy call on Malayan Cement, FV RM3.36
Maybank, Hong Leong Bank and PetDag lead KLCI higher
Net foreign outflow slows to RM108.1mil in holiday-shortened trading
Trading ideas: E&O, Kerjaya Prospek, YTL Corp, AirAsia, Cabnet

Stories You'll Enjoy


Vouchers